Skip to content
StockMarketAgent
Direct answer
Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverage M&A to offset the massive patent cliff approaching in 2028. Fair value range: low $94.9, high $147, with mid-point at $121.
Stock analysis

MRK fair value $95–$147

By StockMarketAgent.AI team· supervised by
Analizzato: 2026-05-08Prossimo aggiornamento: 2026-08-08Methodology v2.5Review: automatedArchetype: Mature dividend
View archive
Prezzo
$112.30
▲ +8.31 (+7.40%)
Valore equo
$121
$95–$147
Valutazione
Mantenere
confidence 84/100
Potenziale rialzo
+7.4%
upside to fair value
Margine di Sicurezza
$102.52
MoS level · 15%
Capitalizzazione
$277.4B
P/E fwd 11.8
Fallback in ingleseIT
Mostrando la fonte in inglese mentre traduciamo
Questo report non è ancora stato tradotto. Aggiorna tra qualche minuto una volta che la coda di traduzione avrà recuperato.

§1 Sintesi

  • Heavy concentration risk in Keytruda, which faces loss of exclusivity in 2028.
  • Dependency on future M&A and ADC pipeline execution to replace lost revenue.
  • Primary valuation anchor focuses on near-term forward earnings over stale trailing cash flows.
Fair value
$121
Margin of safety
+6.9%
Confidence
84/100
Moat
9/10

Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.

$112.30Price
Low $94.87
Mid $120.61
High $146.75

Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverage M&A to offset the massive patent cliff approaching in 2028.

  • Intangible Assets (Patents)
    Intangible Assets (Patents)
  • Economies of Scale
    Economies of Scale
  • Cycle upside
    Accelerating M&A and robust pipeline readouts across the biopharma sector.

§2 Scenario ribassista

A severe stress test assumes structural earnings decline post-2028 as Keytruda revenues drop, combined with a failure to realize ADC revenueRevenueRevenue is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions. and M&A integration issues, compressing gross margins.

Come questa tesi può fallire

Severe Keytruda Cliff

· High

Failure to offset Keytruda LOE through M&A or internal ADC pipeline leaves a massive revenue gap, severely compressing structural margins.

FV impact
Down to $94.87
Trigger
2028-2030

ADC Pipeline Failure

· Medium

Late-stage clinical failures in the Antibody-Drug Conjugate pipeline erode future growth vectors, stalling the dividend trajectory.

FV impact
Loss of terminal growth and multiple derating
Trigger
2026-2028

Draconian IRA Pricing

· Medium

Aggressive regulatory pricing pressures from the IRA compress margins more sharply than modeled, stunting near-term operating cash flows.

FV impact
Terminal margin deterioration
Trigger
2026-2029
Segnali di allerta precoce da monitorare
MetricaAttualeSoglia di attivazione
Slowdown in Keytruda quarterly sales growth pre-2028MonitorDeterioration versus the report thesis
Negative FDA decisions on late-stage ADC candidatesMonitorDeterioration versus the report thesis
Escalating R&D costs without proportional revenue gainsMonitorDeterioration versus the report thesis
Unfavorable shifts in gross margin trajectoriesMonitorDeterioration versus the report thesis
Management signaling a pause or slowing of dividend growthMonitorDeterioration versus the report thesis

§3 Storia finanziaria

Conto economico — ultimi sei periodi
VoceT−0T−1T−2T−3CAGR
Periodo2022-12-312023-12-312024-12-312025-12-31Trend
Ricavi$59.28B$60.12B$64.17B$65.01B+3.1%
Utile lordo$41.87B$43.99B$48.98B$48.63B+5.1%
Reddito operativo$18.28B$2.95B$20.22B$22.11B+6.5%
Utile netto$14.52B$365.0M$17.12B$18.25B+7.9%
EPS (diluito)$5.71$0.14$6.74$7.28+8.4%
EBITDA$21.32B$6.91B$25.71B$28.26B+9.9%
R&S$13.55B$30.53B$17.94B$15.79B+5.2%
SG&A$10.04B$10.50B$10.82B$10.73B+2.2%

Punteggi di qualità

Piotroski F-score
4 / 9
Composito qualità 0–9
Altman Z-score
3.87
Rischio di fallimento (>3 sicuro)
Beneish M-score
-2.27
Rischio di manipolazione degli utili
OCF / Utile netto
0.9×
>1 indica alta qualità degli utili
Soglia di qualità contabile
Pass
Soglia corretta per settore
ROIC
17.4%
Rendimento del capitale investito
Sezione 3

Numbers analysis

Flusso di cassa

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Allocazione del capitale

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Abbonati individuali — da §4 in poi11 sezioni in più

Leggi l'analisi completa — 11 sezioni in più.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Report completo per ogni ticker coperto
24 mesi di archivio rating
Briefing della watchlist + avvisi di variazione del rating
Esportazione PDF + DOCX in qualsiasi lingua
Inizia la prova gratuita
Annulla in qualsiasi momento.
INTRINSIC VALUE FAQ

MRK intrinsic value questions

  1. MRK (MRK)'s intrinsic value is triangulated from discounted earnings at two cost-of-equity levels (strict CAPM with raw beta, moderate with adjusted beta), with owner earnings used as a floor for high-growth names.

FAQ

MRK — frequently asked questions

  1. Based on our latest analysis, MRK looks modestly undervalued. The current price is $112 versus a composite fair-value midpoint of $121 (range $94.9–$147), which implies roughly 7.4% upside to the midpoint.

Related coverage

Names readers of MRK also follow

Same archetype: mature-dividend